Price
No data yet.
Social Signal Score
Revenue
$10.18M+557.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Samarth Kulkarni
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 393
- Beta
- 1.74
- Country
- CH
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.94
Financials
Revenue
$10.18M+557.3%Net Income
$-91.15MEBITDA
$-110.50MFree Cash Flow
$-193.55MEPS (diluted)
$-0.94Shares Outstanding (diluted)
96.51M+142.8%Operating Expenses
$80.41MCash & Debt
$2.36BReturn of Capital
$722.0KRevenue by Segment (annual)
$3.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.51M | $-581.60M | $-6.47 |
| 2024 | $35.00M | $-366.25M | $-4.34 |
| 2023 | $370.00M | $-153.61M | $-1.94 |
| 2022 | $436.0K | $-650.17M | $-8.36 |
| 2021 | $913.08M | $377.66M | $4.97 |
| 2020 | $719.0K | $-348.87M | $-5.29 |
| 2019 | $289.59M | $66.86M | $1.23 |
| 2018 | $3.12M | $-164.98M | $-3.44 |
| 2017 | $41.00M | $-68.36M | $-1.71 |
| 2016 | $5.16M | $-23.20M | $-1.89 |
| 2015 | $247.0K | $-25.83M | $-0.88 |
| 2014 | $0.00 | $-6.80M | $-0.23 |
Valuation
CRSPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newszacks.com·6h ago·Neutral
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report? CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
View source ↗
Earnings
Mon, Nov 9(in 2 months)
Consensus estimate $-1.06 per share
Typical surprise -7.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.94 vs $-1.19beat
- Mon, May 4$-1.28 vs $-1.19miss
- Thu, Feb 12$-1.37 vs $-1.15miss
- Mon, Nov 10$-1.17 vs $-1.26beat
- Tue, Aug 5$-2.40 vs $-1.47miss
- Tue, May 6$-1.58 vs $-1.27miss
Estimates and results for CRSP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRSP officers and directors.
- Bought
- $52.4m
- Sold
- $17.6m
4 trades
27 trades
- Patel Naimishsold
- Kasinger James R.sold
- Kulkarni Samarthsold
- Prasad Rajusold
- Patel Naimishsold
- Prasad Rajusold
- Prasad Rajusold
- Kasinger James R.sold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.